EC5026 oral tablet — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (
Phase 1/2 · Parkinson's Disease (PD) |
EicOsis Human Health Inc. | EC5026 oral tablet |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|